/Companies

Capsulomics

Halethorpe, US · Maryland corporation · 6 known investors

Find your way into Capsulomics

Sign up to see every warm intro you have to Capsulomics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Capsulomics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Capsulomics offers Esopredict, a DNA methylation-based risk-stratification test that predicts progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma for gastroenterologists and pathologists. The test is used as a secondary option when the company's primary TissueCypher spatialomics test cannot provide results.

Founders & leadership

DLDaniel Lunz
Daniel LunzExecutive
WSWilliam Stevens
William StevensChief Financial Officer2021–2025William Stevens is Chief Executive Officer of Capsulomics, which develops DNA methylation-based diagnostic tests for esophageal cancer risk assessment. He previously served as Chief Financial Officer across multiple organizations over 11 years.
SM
Stephen MeltzerNamed on SEC filing

Board

JN
John NeiderhuberBoard director

Investors · 6

Also in the syndicate · 1

Wexford Science and Technology

Funding

SEC filings, press & company announcements

$2.4M disclosed across 1 of 3 rounds · 2019–2023

▶$2.4MraisedMar 2025 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John NeiderhuberDirector
  • Daniel LunzExecutive Officer, Director
  • William StevensExecutive Officer
  • Stephen MeltzerDirector
Offering amount
$3M
Amount sold
$2.4M
First sale
Dec 2019
Incorporated
Corporation, Maryland
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Frequently asked questions

What does Capsulomics do?
Capsulomics offers Esopredict, a DNA methylation-based risk-stratification test that predicts progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma for gastroenterologists and pathologists. The test is used as a secondary option when the company's primary TissueCypher spatialomics test cannot provide results.
Who are Capsulomics's investors?
Capsulomics's investors include Early Light Ventures, Gaingels, Maryland TEDCO, TEDCO, Riptide Ventures.
How much funding has Capsulomics raised?
Capsulomics has disclosed $2.4M raised across 1 of its 3 known rounds.
Where is Capsulomics headquartered?
Capsulomics is headquartered in Halethorpe, US.